Jantec Pharma Private Limited
About Jantec Pharma Private Limited
Data last updated:
Jantec Pharma Private Limited is a private limited company based in Delhi, India. It operates in the retail trading segment of the trading and commerce sector. It was incorporated on 08 June 2010 and has been in existence for over 16 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U24232DL2010PTC203856.
The company has an authorised share capital of ₹1 Lakh and a paid-up capital of ₹1 Lakh. It is led by directors Ashutosh Pataudi and Satpal.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at Flat No 248 Ground Floor Pocket 26, Sector – 24 Landmark Near Rithala Metro Station, Delhi, India – 110085.
As per the financials filed for FY 2025, the company reported a revenue of ₹29,365, a growth of 17% compared to the previous year. Revenue has grown at a compounded annual rate (CAGR) of 6% over three years and 8% over five years.
The current compliance status is marked as compliant by the Registrar of Companies.
Company details
Contact details
Jantec Pharma Private Limited's registered office is in Delhi, Delhi. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Registered AddressFlat No 248 Ground Floor Pocket 26, Sector – 24 Landmark Near Rithala Metro Station, Delhi, India – 110085
- IndustryTrading, Retail Trading, Retailers
To see the full contact details of Jantec Pharma Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Jantec Pharma is real estate. In detail, this covers real estate activities on fee or contract basis.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| L | Real Estate | L2 | Real estate activities on fee or contract basis |
To see the full business activity and turnover split of Jantec Pharma Private Limited, buy the company report.
Financials of Jantec Pharma Private Limited
FY 2025 filings availableJantec Pharma Private Limited reported revenue of ₹29,365 (up 17% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 8% over five years, including 17% growth in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | |||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | |||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | |||||
| Net Profit Margin | |||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Jantec Pharma Private Limited, buy the company report.
Board of directors of Jantec Pharma Private Limited
Jantec Pharma has 2 current directors and 7 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Ashutosh Pataudi Also directs: S P Jindal Industries Limited, Sunwealth International Limited, Sunwealth Real Estates Limited and 5 more | Director | 20 Nov 2019 | 6 Years 11 Months | Current |
| Satpal | Director | 21 Jan 2019 | 7 Years 9 Months | Current |
Peer comparison
Jantec Pharma Private Limited is compared with the 10 companies closest to it by revenue in the same principal business activity (real estate activities on fee or contract basis), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Arth Infraplanners Private Limited | ₹29,850 (FY 2025) | 1.0% | Bareilly, Uttar Pradesh, India | |||
| S.S.D.N. Landbase India Private Limited | ₹29,709 (FY 2024) | 65.0% | Gurgaon, Haryana, India | |||
| Rai Multi Estates Private Limited | ₹29,676 (FY 2024) | 17.0% | Punjab, India | |||
| Mayank Vanijya Private Limited | ₹29,500 (FY 2025) | -22.0% | Raipur, Chhattisgarh, India | |||
| Sunmark Builders Private Limited | ₹29,500 (FY 2024) | 111.0% | Punjab, India | |||
| Jantec Pharma Private Limitedthis company | ₹29,365 (FY 2025) | 17.0% | Delhi, India | |||
| Panchabhuj Construction Private Limited | ₹29,000 (FY 2019) | Thane, Maharashtra, India | ||||
| Ipt Real Estates Private Limited | ₹29,000 (FY 2024) | 314.0% | Indore, Madhya Pradesh, India | |||
| Bright Nirman Private Limited | ₹28,901 (FY 2019) | 2790.0% | Kolkata, West Bengal, India | |||
| Avidaire Portfolio Private Limited | ₹28,769 (FY 2016) | -98.0% | Gurgaon, Haryana, India | |||
| Streamline Infrabuild Private Limited | ₹28,700 (FY 2018) | -49.0% | Lucknow, Uttar Pradesh, India |
To see the full peer comparison of Jantec Pharma Private Limited, buy the company report.
Auditor
Jantec Pharma Private Limited is audited by S P JINDAL & ASSOCIATES for the financial year 2017.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| S P JINDAL & ASSOCIATES | FY 2017 | 020046N |
Shareholding
The shareholding of Jantec Pharma Private Limited is on record for 2 financial years, the latest being FY 2017, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2017 | FY 2016 |
|---|---|---|
| Promoters | ||
| Domestic institutional investors (DII) | ||
| Foreign institutional investors (FII) | ||
| Public | ||
| Others |
To see the full shareholding pattern of Jantec Pharma Private Limited, buy the company report.
Legal cases
No court or tribunal cases involving Jantec Pharma Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Jantec Pharma Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
No GST registration is on our record for Jantec Pharma Private Limited; the GSTIN and return-filing check is in the company report Buy the company report.
Recent activity
Jantec Pharma Private Limited has 9 board changes on record since 2016: 2 appointments and 7 cessations. The latest: Ashutosh Pataudi was appointed as Director on 20 Nov 2019.
Frequently asked questions
Jantec Pharma is an active private limited company based in Delhi, India. The company works in retail trading, within the trading industry. It was incorporated on 08 June 2010 (16+ years old) and is registered under CIN U24232DL2010PTC203856.
Jantec Pharma has 2 current directors:
- Ashutosh Pataudi - Director
- Satpal - Director
The latest financial statements of Jantec Pharma on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The CIN (Corporate Identification Number) of Jantec Pharma is U24232DL2010PTC203856. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Jantec Pharma was incorporated on 08 June 2010, making it 16+ years old. It is registered with the Registrar of Companies, Delhi.
The peers of Jantec Pharma by revenue are Arth Infraplanners Private Limited, S.S.D.N. Landbase India Private Limited, Rai Multi Estates Private Limited, Mayank Vanijya Private Limited, Sunmark Builders Private Limited and 5 more, all in the same principal business activity (real estate activities on fee or contract basis).
Ashutosh Pataudi was appointed as Director on 20 Nov 2019. Sandeep Singhal ceased to be Director on 20 Nov 2019. Satpal ceased to be Additional Director on 29 Sep 2019. Jantec Pharma has 9 board changes on record in total.
The registered office of Jantec Pharma is at Flat No 248 Ground Floor Pocket 26, Sector – 24 Landmark Near Rithala Metro Station, Delhi, India – 110085.
Jantec Pharma operates in the trading industry, in the retail trading segment.
The compliance status of Jantec Pharma is compliant as of 06 July 2026. The company is actively filing with the Registrar of Companies.
Jantec Pharma can be reached at its registered office: Flat No 248 Ground Floor Pocket 26, Sector – 24 Landmark Near Rithala Metro Station, Delhi, India – 110085.